Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture
Open accessAbstract
BACKGROUND: Treatment of resistant hypertension has attained much attention during the past few years and naturally so has the prevalence of resistant hypertension. In the search for sources of such documentation, the lack of blood pressure (BP) control in randomized clinical outcome trials in hypertension has been used as indication of treatment-resistant hypertension. In the present study, we aimed at using previously unpublished information from monitoring of clinical trials in investigating the mechanism explaining why large fractions of patients in the trials remained uncontrolled for their high BP. METHODS: We report insight information from LIFE (n = 9193), VALUE (n = 15,245), ASCOT (n = 19,257) and ACCOMPLISH (n = 11,506). Data stored during the course of the trials for monitoring purposes were scrutinized for fractions of patients with BP control, which was BP < 140/90 mmHg in all trials, and we identified monitoring data showing fractions of patients who had been uptitrated to the various dosing levels or combinations of study drugs in the trials. Fractions of patients who had not been uptitrated on drugs and who remained without BP control identified the level of physician (investigator) inertia in these trials. RESULTS: In the LIFE Study the majority of patients remained with systolic BP > 140 mmHg throughout. Approximately 1500 patients remained on the first dose titration step despite not having reached target BP. In the VALUE Trial 59.5% had reached systolic BP target 2 years into the study; 23.9% of patients remained on the lowest study dose and only 15.1% had been uptitrated to the highest study dose. In the ASCOT Trial, as many as 28% of participants had not reached target diastolic BP at year 4 in the study, and of these patients 37% still remained on the first drug dose titration step. In the ACCOMPLISH Trial approximately 80% had achieved the systolic BP target at study end; however, during the course of the trial approximately 25% of participants remained uncontrolled and at 6 months almost 60% of these patients had not been titrated to the highest drug dose level. CONCLUSION: These data, taken from the monitoring phases of large outcome trials in hypertension, show that inertia, the lack of titration of study drugs to higher dosing levels or drug combinations according to the study protocols, is a major cause of not reaching BP targets in the trials. Thus, fractions of patients not reaching BP targets in outcome trials cannot be taken as evidence of treatment-resistant hypertension.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Suboptimal medication regimens are common in patients with hypertension resistant to antihypertensive therapy.
“Suboptimal medication regimens are common in patients with hypertension resistant to antihypertensive therapy.21,60,367”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [367]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · see citing works
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407 · see citing works
Self-citationDahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909 · see citing works
Self-citationJulius, S., Kjeldsen, S. E., Weber, M. A., Brunner, H. R., Ekman, S., Hansson, L., Hua, T. A., Laragh, J. H., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,546 · see citing works
Self-citationBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065 · see citing works
Self-citationde la Sierra, A., Segura, J., Banegas, J. R., Gorostidi, M., de la Cruz, J. J., Armario, P., Oliveras, A., & Ruilope, L. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168948 · Cited by 809 · see citing works
Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008
Egan, B. M., Zhao, Y., Axon, R. N., Brzezinski, W. A., & Ferdinand, K. C. (2011) · Circulation · doi:10.1161/circulationaha.111.030189 · Cited by 599 · see citing works
Gupta, A. K., Nasothimiou, E. G., Chang, C. L., Sever, P. S., Dahlöf, B., & Poulter, N. R. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834a8a42 · Cited by 165 · see citing works
Self-citationExceptional early blood pressure control rates: The ACCOMPLISH trial
Jamerson, K., Bakris, G. L., Dahlöf, B., Pitt, B., Velazquez, E., Gupte, J., Lefkowitz, M., Hester, A., Shi, V., Kjeldsen, S. E., et al. (2007) · Blood Pressure · doi:10.1080/08037050701395571 · Cited by 125 · see citing works
Self-citationJulius, S. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00904-x · Cited by 117 · see citing works
Self-citationFactors associated with therapeutic inertia in hypertension: validation of a predictive model
Redón, J., Coca, A., Lázaro, P., Aguilar, M. D. J., Cabañas, M., García, N. G., Sanchez-Zamorano, M. A., & Aranda, P. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833b4953 · Cited by 114 · see citing works
Kjeldsen, S., Dahlöf, B., Devereux, R. B., Julius, S., Fairé, U. D., Fyhrquist, F., Ibsen, H., Kristianson, K. J., Lederballe‐Pedersen, O., Lindholm, L. H., et al. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)00280-6 · Cited by 60 · see citing works
Self-citationNever mind the quality, feel the width – ALLHAT revisited
McInnes, G. T., & Kjeldsen, S. E. (2004) · Blood Pressure · doi:10.1080/08037050410004576 · Cited by 12 · see citing works
Self-citationResistant hypertension revisited
Modolo, R., de Faria, A. P., Sabbatini, A. R., & Moreno, H. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000219 · Cited by 6 · see citing works
Medikamentvalg ved hypertensjon
Schultz, M., Aksnes, T. A., Høieggen, A., & Kjeldsen, S. E. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.13.0311 · Cited by 3 · see citing works
Self-citationResistance to antihypertensive treatment
de Leeuw, P. W. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834b8b52 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Julius S , Kjeldsen SE , Weber M , Brunner H , Ekman S , 4. Hansson L et al . Cardiac events, stroke and mortality in high- risk hypertensives treated with valsartan or amlodipine: Main outcomes of The VALUE Trial . Lancet. 2004 ; 363 : 2022 -31 .
- Modolo R , Faria APD , Sabbatini AR , Moreno H . Resistant 16. hypertension revisited: Defi nition and true prevalence . J Hypertens. 2014 ; 32 : 1546 .
Cited by
Sorted by citations
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473 · see citing works
Self-citationCarey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
Azizi, M., Pereira, H., Hamdidouche, I., Gosse, P., Monge, M., Bobrie, G., Delsart, P., Mounier‐Véhier, C., Courand, P., Lantelme, P., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.022922 · Cited by 153 · see citing works
Two-Drug Combinations as First-Step Antihypertensive Treatment
Mancia, G., Rea, F., Corrao, G., & Grassi, G. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313294 · Cited by 130 · see citing works
Why in 2016 are patients with hypertension not 100% controlled? A call to action
Redón, J., Mourad, J., Schmieder, R. E., Volpe, M., & Weiss, T. W. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000988 · Cited by 74 · see citing works
KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Kramer, H., Townsend, R. R., Griffin, K. A., Flynn, J. T., Weiner, D. E., Rocco, M. V., Choi, M. J., Weir, M. R., Chang, T. I., Agarwal, R., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.01.007 · Cited by 37 · see citing works
Lee, C. J., Park, W. J., Suh, J., Choi, E., Jeon, D. W., Lim, S., Kim, D., Cha, K. S., Lee, B.-R., Kim, N., et al. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13941 · Cited by 32 · see citing works
Zhang, X., Meng, F., Song, J., Zhang, L., Wang, J., Li, D., Li, L., Dong, P., Yang, B., & Chen, Y. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000316 · Cited by 31 · see citing works
Backer, T. L. M. D., Nieuwenhuyse, B. V., & Bacquer, D. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248471 · Cited by 30 · see citing works
Heimark, S., Mehlum, M. H., Mancia, G., Søraas, C. L., Liestøl, K., Wachtell, K., Larstorp, A. C. K., Rostrup, M., Mariampillai, J. E., Kjeldsen, S. E., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21454 · Cited by 30 · see citing works
Self-citationSugar-sweetened beverages and school students’ hypertension in urban areas of Nanjing, China
Qin, Z., Xu, F., Ye, Q., Zhou, H., Li, C., He, J., Wang, Z., Hong, X., & Hou, X. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0030-9 · Cited by 28 · see citing works
Pallarés‐Carratalá, V., Bonig-Trigueros, I., Palazón‐Bru, A., Esteban-Giner, M. J., Gil-Guillén, V. F., & Galvañ, V. G. (2019) · Blood Pressure · doi:10.1080/08037051.2019.1608134 · Cited by 26 · see citing works
Regression to the mean in home blood pressure: Analyses of the BP GUIDE study
Wang, N., Atkins, E., Salam, A., Moore, M. N., Sharman, J. E., & Rodgers, A. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13933 · Cited by 24 · see citing works
Successes of SPRINT, but Still Some Hurdles to Cross
Touyz, R. M., & Dominiczak, A. F. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06725 · Cited by 23 · see citing works
Establishing Serum Reference Ranges for Antihypertensive Drugs
Rognstad, S., Søraas, C. L., Bergland, O. U., Høieggen, A., Strømmen, M., Helland, A., & Opdal, M. S. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000806 · Cited by 23 · see citing works
Sarganas, G., & Neuhauser, H. K. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12886 · Cited by 22 · see citing works
Emerging concepts for patients with treatment-resistant hypertension
Eirin, A., Textor, S. C., & Lerman, L. O. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.05.004 · Cited by 21 · see citing works
König, M., Gollasch, M., Rosada, A., Demuth, I., Spira, D., & Steinhagen‐Thiessen, E. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0580-0 · Cited by 14 · see citing works
Renal denervation in treatment-resistant hypertension: a reappraisal
Persu, A., Jin, Y., Elmula, F. E. M. F., Renkin, J. P., Høieggen, A., Kjeldsen, S. E., & Staessen, J. A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.013 · Cited by 13 · see citing works
Self-citationRognstad, S., Søraas, C. L., Brunborg, C., Halvorsen, L. V., Brobak, K. M., Olsen, E., Bergland, O. U., Aune, A., Tuv, S. S., Svarstad, A. C., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70140 · Cited by 11 · see citing works
Clinical Diagnosis and Management of Resistant Hypertension
Tsioufis, C. P., Kasiakogias, A., & Tousoulis, D. M. (2016) · European Cardiology Review · doi:10.15420/ecr.2016:1:2 · Cited by 11 · see citing works
Halvorsen, L. V., Søraas, C. L., Larstorp, A. C. K., Hjørnholm, U., Kjær, V. N., Liestøl, K., Aune, A., Olsen, E., Brobak, K. M., Bergland, O. U., et al. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae059 · Cited by 11 · see citing works
Self-citationRandomized Clinical Outcome Trials in Hypertension
Mancia, G., & Kjeldsen, S. E. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21725 · Cited by 11 · see citing works
Self-citationPEAR1 gene polymorphism in a Chinese pedigree with pulmonary thromboembolism
Fu, Y., Sun, S., Liang, J., Liu, S., Jiang, Y., Xu, L., & Mei, J. (2016) · Medicine · doi:10.1097/md.0000000000005687 · Cited by 8 · see citing works
Zhang, Y., Shui, W., Tian, Y., Zhang, Z., Li, J., & Wang, J. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02018-1 · Cited by 7 · see citing works
Sakulsupsiri, A., Chattranukulchai, P., Siwamogsatham, S., Boonchaya‐anant, P., Naeowong, W., Ariyachaipanich, A., Lertsuwunseri, V., Rungpradubvong, V., Satitthummanid, S., Puwanant, S., et al. (2021) · International Journal of Hypertension · doi:10.1155/2021/8844727 · Cited by 6 · see citing works
Burnier, M. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2363401 · Cited by 5 · see citing works
Olsen, E., Søraas, C. L., Schmieder, R. E., Jamerson, K., MacDonald, T. M., Mancia, G., Heimark, S., Mehlum, M. H., Liestøl, K., Larstorp, A. C. K., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf093 · Cited by 4 · see citing works
Self-citationSalam, A., Webster, R. J., Patel, A. A., Godamunne, P., Pathmeswaran, A., de Silva, H. A., Rogers, A., Jan, S., & Laba, T. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022317 · Cited by 4 · see citing works
Raising the Bar in Renal Sympathetic Denervation Research and Reporting
Lee, J., & Turner, J. R. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12666 · Cited by 3 · see citing works
Medical Measures in Hypertensives Considered Resistant
Elmula, F. E. M. F., Mariampillai, J. E., Heimark, S., Kjeldsen, S. E., & Burnier, M. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad118 · Cited by 3 · see citing works
Self-citationChemical adherence testing in the clinical management of hypertension: a scoping review
Rabbitt, L., Curneen, J. M. G., Dennedy, M. C., & Molloy, G. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1452464 · Cited by 2 · see citing works
How can we increase the efficacy of antihypertensive treatment?
Özyüncü, N., & Erol, Ç. (2024) · Kardiologia Polska · doi:10.33963/v.kp.98705 · Cited by 2 · see citing works
Butler, S., Holt, N., Dai, F., Quick, C., Kravetz, J. D., Perrino, A. C., & Schonberger, R. B. (2024) · Cureus · doi:10.7759/cureus.58401 · Cited by 1 · see citing works
Burnier, M., Narkiewicz, K., & Oparil, S. (2021) · Blood Pressure · doi:10.1080/08037051.2021.1878324 · Cited by 1 · see citing works
Manolis, A. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734299250.793571584 · Cited by 1 · see citing works
Hypertension; Grey Zones, Future Perspectives
Andreadis, E. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-39599-9_22
Interventions to improve adherence of antihypertensive medication in African-Americans
Kjeldsen, S. E., & Os, I. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001249
Self-citationKichou, B., Henine, N., Kichou, L., Boubchir, M. A., Saïd, M. A., Zatout, M. M. M., Hammouche, A., Mazeghrane, A., Madiou, A., & Benbouabdellah, M. (2018) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2018.04.010
Why we still don't achieve blood pressure targets
Tuka, V., & Linhart, A. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.095
Medication adherence: An overlooked critical determinant of pharmacological effectiveness
Burnier, M., Azizi, M., Gupta, P., Kardas, P., Schneider, M. P., & Vrijens, B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100161
- Authors
- Kjeldsen, S. E., Julius, S., Dahlöf, B., & Weber, M. A.
- Affiliations
- Oslo University Hospital (NO)
- Michigan Medicine (US)
- Sahlgrenska University Hospital (SE)
- SUNY Downstate Health Sciences University (US)
- Corresponding author
- Kjeldsen, Sverre E.
- Venue
- Blood Pressure
- Publisher
- Informa UK Limited
- Published
- 2014-08-27
- Volume
- 24
- Issue
- 1
- Pages
- 1-6
- ISSN
- 0803-7051 (ISSN-L)
- 1651-1999
- OpenAlex
- W2082237858
- Cited by
- 41
- References
- 16
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 4 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 7 · 2015: 4
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood Pressure (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- resistant hypertension, blood pressure control, treatment-resistant hypertension, LIFE trial, VALUE trial, ASCOT trial, ACCOMPLISH trial, combination antihypertensive therapy, antihypertensive medication adherence
- MeSH terms
- Blood Pressure, Female, Humans, Hypertension, Male, Physicians, Randomized Controlled Trials as Topic, Databases, Factual, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
